This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2013 Jan 16;1(1):1.

doi: 10.1186/2050-7771-1-1.

Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials

Chung-Tsen Hsueh¹, Delong Liu, Hong Wang

Affiliations

PMID: 24252729
PMCID: PMC3776243
DOI: 10.1186/2050-7771-1-1

Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials

Chung-Tsen Hsueh et al. Biomark Res. 2013.

. 2013 Jan 16;1(1):1.

doi: 10.1186/2050-7771-1-1.

Authors

Chung-Tsen Hsueh¹, Delong Liu, Hong Wang

Affiliation

¹ New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA. delong_liu@nymc.edu.

PMID: 24252729
PMCID: PMC3776243
DOI: 10.1186/2050-7771-1-1

No abstract available

PubMed Disclaimer

Similar articles

Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL.
Kittai AS, Lunning M, Danilov AV. Kittai AS, et al. Curr Hematol Malig Rep. 2019 Aug;14(4):302-309. doi: 10.1007/s11899-019-00511-1. Curr Hematol Malig Rep. 2019. PMID: 31049852 Review.
Novel biomarkers for the diagnosis and prognosis of gallbladder cancer.
Lin HZ, Zhang T, Chen MY, Shen JL. Lin HZ, et al. J Dig Dis. 2021 Feb;22(2):62-71. doi: 10.1111/1751-2980.12966. J Dig Dis. 2021. PMID: 33369216 Review.
Integrating biomarkers in clinical trials.
Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A. Buyse M, et al. Expert Rev Mol Diagn. 2011 Mar;11(2):171-82. doi: 10.1586/erm.10.120. Expert Rev Mol Diagn. 2011. PMID: 21405968 Review.
Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review.
Montalvo-Jave EE, Rahnemai-Azar AA, Papaconstantinou D, Deloiza ME, Tsilimigras DI, Moris D, Mendoza-Barrera GE, Weber SM, Pawlik TM. Montalvo-Jave EE, et al. Surg Oncol. 2019 Dec;31:83-89. doi: 10.1016/j.suronc.2019.09.006. Epub 2019 Sep 13. Surg Oncol. 2019. PMID: 31541911 Review.
Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
Kamel HFM, Al-Amodi HSAB. Kamel HFM, et al. Genomics Proteomics Bioinformatics. 2017 Aug;15(4):220-235. doi: 10.1016/j.gpb.2016.11.005. Epub 2017 Aug 13. Genomics Proteomics Bioinformatics. 2017. PMID: 28813639 Free PMC article. Review.

See all similar articles

Cited by

Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.
Srinivas NR. Srinivas NR. Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):373-382. doi: 10.1007/s13318-018-0466-x. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29488172 Review.
A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data.
Kern DM, Barron JJ, Wu B, Ganetsky A, Willey VJ, Quimbo RA, Fisch MJ, Singer J, Nguyen A, Mamtani R. Kern DM, et al. Pragmat Obs Res. 2017 Aug 26;8:149-155. doi: 10.2147/POR.S140579. eCollection 2017. Pragmat Obs Res. 2017. PMID: 28894396 Free PMC article.
A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.
Deibler KK, Mishra RK, Clutter MR, Antanasijevic A, Bergan R, Caffrey M, Scheidt KA. Deibler KK, et al. ACS Chem Biol. 2017 May 19;12(5):1245-1256. doi: 10.1021/acschembio.6b01060. Epub 2017 Mar 20. ACS Chem Biol. 2017. PMID: 28263556 Free PMC article.
B-Raf and the inhibitors: from bench to bedside.
Huang T, Karsy M, Zhuge J, Zhong M, Liu D. Huang T, et al. J Hematol Oncol. 2013 Apr 25;6:30. doi: 10.1186/1756-8722-6-30. J Hematol Oncol. 2013. PMID: 23617957 Free PMC article. Review.
A new role of ¹¹ C-Choline PET in localizing the epileptogenic foci in insular cortex in the patients.
Chen YF, Wei R, Yuan GQ, Gao DD, Jin Q, Cui XY, Zhang GX, Guo J. Chen YF, et al. CNS Neurosci Ther. 2020 Jan;26(1):144-147. doi: 10.1111/cns.13215. Epub 2019 Sep 11. CNS Neurosci Ther. 2020. PMID: 31508896 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath SM, Liu D. Recent advances and novel agents for gastrointestinal stromal tumor (GIST) J Hematol Oncol. 2012;5:21. doi: 10.1186/1756-8722-5-21. - DOI - PMC - PubMed
1. Lamba G, Gupta R, Lee B, Ambrale S, Liu D. Current management and prognostic features for gastrointestinal stromal tumor (GIST) Experimental Hematology & Oncology. 2012;1(1):14. doi: 10.1186/2162-3619-1-14. - DOI - PMC - PubMed
1. Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5:3. doi: 10.1186/1756-8722-5-3. - DOI - PMC - PubMed
1. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP. et al.Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–2259. doi: 10.1056/NEJMoa0912614. - DOI - PubMed
1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M. et al.Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516. doi: 10.1056/NEJMoa1103782. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations